HomeProductsBioactive CompoundsTransporters & Ion ChannelsGlycine TransporterBitopertin
Chemical structure of CAS 845614-11-1

Bitopertin

CAS No.845614-11-1
MDL No.MFCD18251496
MFC21H20F7N3O4S
MW543.50
InChI KeyYUUGYIUSCYNSQR-LBPRGKRZSA-N

Pricing & Availability

Pack SizePurityPriceAvailabilityAction
- -On RequestOn Request
Custom synthesis and bulk supply options are available upon request.

Product Information

CAS No.845614-11-1
Product NameBitopertin

Biological Targets

SLC6A9

Associated Conditions

obsessive-compulsive disorder·schizophrenia·Diamond-Blackfan anemia·Beta-thalassemia·erythropoietic protoporphyria
* The information provided here is compiled from public sources and is for reference only.

Related Articles

Studies related to this compound and its mechanism of action

Discovery of Novel Aminotetralines and Aminochromanes as Selective and Competitive Glycine Transporter 1 (GlyT1) Inhibitors.

Journal of medicinal chemistry • Vol. 61, Issue 17 • 2018
PMID: 30080045DOI: 10.1021/acs.jmedchem.8b00300

Bitopertin in Negative Symptoms of Schizophrenia-Results From the Phase III FlashLyte and DayLyte Studies.

Biological psychiatry • Vol. 82, Issue 1 • 2017
PMID: 28117049DOI: 10.1016/j.biopsych.2016.11.014

Efficacy and safety of adjunctive bitopertin versus placebo in patients with suboptimally controlled symptoms of schizophrenia treated with antipsychotics: results from three phase 3, randomised, double-blind, parallel-group, placebo-controlled, multicentre studies in the SearchLyte clinical trial programme.

The lancet. Psychiatry • Vol. 3, Issue 12 • 2016
PMID: 27816567DOI: 10.1016/S2215-0366(16)30344-3

A phase II/III trial of bitopertin monotherapy compared with placebo in patients with an acute exacerbation of schizophrenia - results from the CandleLyte study.

European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology • Vol. 24, Issue 7 • 2014
PMID: 24735806DOI: 10.1016/j.euroneuro.2014.03.007

Documentation